SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Orphan drug development is progressing too slowly
0 references·6 citing·19 second hop
Orphan drug development is progressing too slowly (2006)Orphan drug development is progressing to…Rare lung disease and orphan drug development (2013)Rare lung disease and orphan …Unintended effects of orphan product designation for rare neurological diseases (2012)Unintended effects of orphan …Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007 (2010)Global Spending on Orphan Dru…Orphan drug development is not taking off (2009)Orphan drug development is no…Predictors of orphan drug approval in the European Union (2008)Predictors of orphan drug app…Orphan drug legislation: lessons for neglected tropical diseases (2008)Orphan drug legislation: less…Rare diseases and orphan drugs (2006)Why rare diseases are an important medical and social issue (2008)An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences (2011)Why we should care about ultra-rare disease (2016)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)National Institute for Clinical Excellence and its value judgments (2004)Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe (2010)Drugs for Rare Diseases: Influence of Orphan Designation Status on Price (2011)Orphan drugs and the NHS: should we value rarity? (2005)A journey of hope: lessons learned from studies on rare diseases and orphan drugs (2006)The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? (2009)Access to Essential Drugs in Poor Countries (1999)Drug development for neglected diseases: a deficient market and a public-health policy failure (2002)Pharmaceuticals and the Developing World (2002)Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research? (2013)Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments (2020)Official Journal of the European Communities (1984)Priority Medicines for Europe and the World "A Public Health Approach to Innovation" (2013)Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2009Orphan drug development is not taking off63 cited
  • 2008Orphan drug legislation: lessons for neglected tropical diseases61 cited
  • 2010Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 200757 cited
  • 2008Predictors of orphan drug approval in the European Union53 cited
  • 2013Rare lung disease and orphan drug development50 cited
  • 2012Unintended effects of orphan product designation for rare neurological diseases49 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work